Platform Optimization for Efficient AAV Purification

smartmockups_kzidacni
Over the last decade, the number of clinical trials involving recombinant adeno-associated viral (AAV) vectors has dramatically increased, the diversity of serotypes has expanded and the demand for larger quantities of highly purified material manufactured to cGMP standards has rocketed.

Download this whitepaper to discover how a contract development and manufacturing organization was able to:

Establish an AAV production platform
Implement one single chromatography media to purify various AAV stereotypes

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This content is copyright protected. Any public or private use of this content is subject to prevailing copyright laws. Please contact Technology Networks for permission requests.